-
Mashup Score: 1
Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0AHN Cancer Institute Unveils State-of-the-Art Skin Cancer Center at West Penn Hospital - 6 month(s) ago
Allegheny Health Network Cancer Institute unveiled its new, state-of-the-art Skin Cancer Center at West Penn Hospital, featuring a first-in-the-region full-body 3D imaging system that provides custom digital surveillance for skin abnormalities.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
AHN Cancer Institute Unveils State-of-the-Art Skin Cancer Center at West Penn Hospital @DavidBartlettMD @ahntoday #melsm https://t.co/ZE6KzqSorv
-
-
Mashup Score: 2Neoadjuvant Daromun Elicits RFS Benefit in Locally Advanced, Fully Resectable Melanoma - 7 month(s) ago
Neoadjuvant treatment with intratumoral daromun led to a statistically significant and clinically meaningful improvement in recurrence-free survival compared with surgery alone in patients with locally advanced, fully resectable melanoma, meeting the primary end point of the phase 3 PIVOTAL trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Neoadjuvant treatment with intratumoral daromun led to an improvement in RFS compared w/ surgery alone in patients w/ locally advanced, fully resectable melanoma, meeting the primary end point of the phase 3 PIVOTAL trial. #melsm https://t.co/WbbTMY3o5d
-
-
Mashup Score: 1
The FDA has approved nivolumab (Opdivo) for the adjuvant treatment of adult and pediatric patients 12 years of age and older with completely resected stage IIB or IIC melanoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The regulatory decision was supported by data from the phase 3 CheckMate76K trial, where patients treated with adjuvant nivolumab experienced a 58% reduction in the risk of recurrence, new primary melanoma, or death vs placebo. @US_FDA #melsm #oncology https://t.co/uX0Tke6kYu https://t.co/sh67hGuqMR
-
-
Mashup Score: 0Neoadjuvant Daromun Meets Primary End Point of RFS in Melanoma - 7 month(s) ago
A trial of intratumoral daromun and surgical resection for the treatment of patients with locally advanced, fully resectable melanoma, showed a clinically meaningful improvement compared with surgery alone.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant intratumoral daromun met its primary end point of recurrence-free survival in locally advanced, fully resectable melanoma, according to findings from the phase 3 PIVOTAL trial. #melsm https://t.co/9m0IRoYyCX
-
-
Mashup Score: 0FDA Approves Adjuvant Nivolumab for Stage IIB/C Melanoma - 7 month(s) ago
The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma. #oncology #nursing #melanoma #melsm https://t.co/AdJdOpZC5s
-
-
Mashup Score: 1Discussing Rationale for Combination Therapy in Metastatic Melanoma - 7 month(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, and participants discussed which first-line therapy they would recommend for a 78-year-old patient with metastatic melanoma and no BRAF-activating mutation. This is the first of 2 articles based on this event.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hussein A. Tawbi, MD, PhD, of @MDAndersonNews and participants discussed which first-line therapy they would recommend for a 78-year-old patient with metastatic melanoma and no BRAF-activating mutation. #melsm https://t.co/Ku1mhFim4G https://t.co/DG6jLj9mnj https://t.co/jTbiYRXwJU
-
-
Mashup Score: 4Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results - 7 month(s) ago
PURPOSE Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial. PIVOT IO 001 (ClinicalTrials.gov identifier: NCT03635983) is a phase III, randomized, open-label study that builds on the PIVOT-02 results in first-line melanoma. METHODS Patients with previously untreated, unresectable, or metastatic melanoma were randomly assigned 1:1 to receive BEMPEG plus nivolumab (NIVO) or NIVO monotherapy. Primary end points were objective response rate (ORR) and progression-free survival (PFS) by blinded independent central review and overall survival (OS). Secondary and exploratory end points included additional efficacy measures, safety, and pharmacokinetics (PKs) and pharmacodynamics analyses. RESULTS In 783 patients (n = 391, BEMPEG plus NIVO; n = 392, NIVO monotherapy), the median follow-up was 11.6 m
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👎 PIVOT Trial: Bempegaldesleukin plus nivolumab in untreated advanced #Melanoma did not improve response or survival. ➡️ https://t.co/0ezShCQFEj #melsm #immunotherapy #ImmunoOnc https://t.co/REV41BfqVp
-
-
Mashup Score: 1
On October 13, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage IIB or IIC melanoma in patients aged 12 years and older. Efficacy was evaluated in CheckMate 76K (ClinicalTrials.gov identifier NCT04099251), a randomized, double-blind trial enrolling 790 patients with stage IIB/IIC melanoma. Patients were randomly assigned 2:1 to receive either nivolumab at 480 mg or placebo by intravenous inf usion every 4 weeks for up to 1
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma https://t.co/QcuHNmzm7p @FDAOncology #melsm #melanoma
-
-
Mashup Score: 1FDA Approves Adjuvant Nivolumab for Stage IIB/C Melanoma - 7 month(s) ago
The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breaking: FDA Approves Adjuvant Nivolumab for Stage IIB/C Melanoma #oncology #nursing #melanoma #melsm https://t.co/AdJdOpZC5s
-
WATCH: @OmidHamidMD, of @CSCancerCenter, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors. #melsm https://t.co/vxQftcy1j8